Keyword: Denali Therapeutics
Denali will acquire the rights to bispecific antibodies targeting the blood-brain barrier that were developed under its collaboration with F-star.
A team of scientists clarified the role of the protein LRRK2 in tuberculosis, suspecting that it behaves similarly in Parkinson's.
Researchers at Washington University School of Medicine have found that targeting the APOE protein helps clear Alzheimer's plaques in mice.
Cleveland Clinic researchers depleted BACE1 to reverse amyloid plaque formation in mice with Alzheimer's disease.
Hard on the heels of a big IPO and a lucrative deal with Takeda, one of Denali’s top execs is leaving the company to join anti-aging startup Alkahest.
Takeda has struck two deals this morning as it looks to make good on its ongoing R&D reorganization.
While 2016 was a year of cancelled and low-end IPOs, 2017 was a year marked by IPO momentum.
The IPO sets Denali up to push drugs against Alzheimer’s and Parkinson’s diseases through early clinical trials.
Heavily backed biotechs Denali Therapeutics and Odonate Therapeutics are looking to make hay while the sun shines by filing for two big IPOs.